Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.

Vansteenkiste J, Wauters I.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1347-55. Review.

PMID:
17944560
2.

Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.

Vansteenkiste JF.

Cancer Treat Rev. 2006;32 Suppl 2:S11-5.

PMID:
16725268
3.

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

Wauters I, Vansteenkiste J.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1383-90. doi: 10.1586/era.12.117. Epub 2012 Oct 31. Review.

PMID:
23113603
4.

Phase III clinical trials with darbepoetin: implications for clinicians.

Glaspy J.

Best Pract Res Clin Haematol. 2005;18(3):407-16. Review.

PMID:
15792914
5.

Darbepoetin alfa: potential role in managing anemia in cancer patients.

Pirker R, Smith R.

Expert Rev Anticancer Ther. 2002 Aug;2(4):377-84. Review.

PMID:
12647980
6.

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia.

Wauters I, Vansteenkiste J.

Expert Opin Biol Ther. 2009 Feb;9(2):221-30. doi: 10.1517/14712590802652280 . Review.

PMID:
19236252
7.

Chemotherapy-induced anemia: the story of darbepoetin alfa.

Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M.

Curr Med Res Opin. 2013 Apr;29(4):325-37. doi: 10.1185/03007995.2013.766593. Epub 2013 Feb 11. Review.

PMID:
23323876
8.

The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.

Vansteenkiste J, Wauters I.

Expert Opin Pharmacother. 2005 Mar;6(3):429-40. Review.

PMID:
15794734
9.

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.

20030125 Study Group Trial, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.

J Clin Oncol. 2006 May 20;24(15):2290-7.

PMID:
16710026
10.

Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.

Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.

Oncologist. 2006 Apr;11(4):409-17.

11.
12.

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

Cersosimo RJ, Jacobson DR.

Ann Pharmacother. 2006 Jan;40(1):58-65; quiz 169-70. Epub 2005 Dec 6. Review.

PMID:
16332942
14.

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly.

Eur J Cancer. 2007 Jan;43(2):258-70. Epub 2006 Dec 19. Review.

PMID:
17182241
15.

Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.

Case AS, Rocconi RP, Kilgore LC, Barnes MN.

Gynecol Oncol. 2006 Jun;101(3):499-502. Epub 2006 Jan 10.

PMID:
16406064
16.

Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV.

Am J Health Syst Pharm. 2005 Jan 1;62(1):54-62.

PMID:
15658073
17.

Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.

Glaspy J.

Oncology (Williston Park). 2006 Jul;20(8 Suppl 6):29-32. Review.

18.

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group.

Curr Med Res Opin. 2009 Sep;25(9):2109-20. doi: 10.1185/03007990903084164.

PMID:
19601709
19.

Darbepoetin alfa for the treatment of cancer-related anemia: an update.

Pirker R.

Expert Rev Anticancer Ther. 2004 Oct;4(5):735-44. Review.

PMID:
15485310
20.

Supplemental Content

Support Center